Dimensional Fund Advisors
EGRX

Dimensional Fund Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Dimensional Fund Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-171,091
Closed -$897K – 3423
2024
Q1 		$897K Sell
171,091
-75,406
-31% -$414K ﹤0.01% 2941
2023
Q4 		$1.29M Sell
246,497
-34,191
-12% -$338K ﹤0.01% 2884
2023
Q3 		$4.43M Sell
280,688
-119,811
-30% -$2.15M ﹤0.01% 2568
2023
Q2 		$7.79M Sell
400,499
-57,813
-13% -$1.37M ﹤0.01% 2365
2023
Q1 		$13M Buy
458,312
+108,706
+31% +$3.23M ﹤0.01% 2112
2022
Q4 		$10.2K Sell
349,606
-6,153
-2% -$196K ﹤0.01% 2198
2022
Q3 		$9.4M Buy
355,759
+38,083
+12% +$1.4M ﹤0.01% 2179
2022
Q2 		$14.1M Buy
317,676
+12,892
+4% +$592K 0.01% 2046
2022
Q1 		$15.1M Buy
304,784
+15,055
+5% +$723K ﹤0.01% 2118
2021
Q4 		$14.8M Buy
289,729
+9,109
+3% +$472K ﹤0.01% 2152
2021
Q3 		$15.7M Sell
280,620
-20,557
-7% -$1.01M 0.01% 2115
2021
Q2 		$12.9M Sell
301,177
-26,730
-8% -$1.1M ﹤0.01% 2245
2021
Q1 		$13.7M Buy
327,907
+20,897
+7% +$970K ﹤0.01% 2199
2020
Q4 		$14.3M Buy
307,010
+8,718
+3% +$408K 0.01% 2127
2020
Q3 		$12.7M Buy
298,292
+3,552
+1% +$155K 0.01% 2080
2020
Q2 		$14.1M Sell
294,740
-1,379
-0.5% -$68.8K 0.01% 2050
2020
Q1 		$13.6M Buy
296,119
+6,875
+2% +$345K 0.01% 1960
2019
Q4 		$17.4M Buy
289,244
+16,034
+6% +$956K 0.01% 2110
2019
Q3 		$15.5M Buy
273,210
+25,162
+10% +$1.42M 0.01% 2150
2019
Q2 		$13.8M Buy
248,048
+116,443
+88% +$6.07M 0.01% 2248
2019
Q1 		$6.64M Hold
131,605
– – ﹤0.01% 2557
2018
Q4 		$5.3M Buy
131,605
+48,359
+58% +$2.49M ﹤0.01% 2587
2018
Q3 		$5.77M Buy
83,246
+30,410
+58% +$2.31M ﹤0.01% 2636
2018
Q2 		$4M Buy
52,836
+22,960
+77% +$1.44M ﹤0.01% 2721
2018
Q1 		$1.57M Sell
29,876
-496
-2% -$28.8K ﹤0.01% 2906
2017
Q4 		$1.62M Sell
30,372
-2,314
-7% -$129K ﹤0.01% 2893
2017
Q3 		$1.95M Buy
32,686
+388
+1% +$23.5K ﹤0.01% 2866
2017
Q2 		$2.55M Buy
32,298
+24,861
+334% +$2.03M ﹤0.01% 2796
2017
Q1 		$617K Hold
7,437
– – ﹤0.01% 3064
2016
Q4 		$590K Buy
+7,437
New +$540K ﹤0.01% 3065

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors's EGRX Position: Q2 2024 in Review

Dimensional Fund Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2024, closing a stake of 171,091 shares — an estimated $897K sold.

Dimensional Fund Advisors first reported a position in EGRX in Q4 2016 and held it in 30 quarters. The position peaked at $17.4M in Q4 2019. 75 funds tracked by Wall St. Rank hold EGRX as of Q2 2024.

  • Dimensional Fund Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Dimensional Fund Advisors sold 171,091 Eagle Pharmaceuticals, Inc. shares in Q2 2024, an estimated $897K.
  • Dimensional Fund Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2016 and held it in 30 quarters.
  • Dimensional Fund Advisors's Eagle Pharmaceuticals, Inc. position peaked at $17.4M in Q4 2019.
  • 75 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2024.

Based on Dimensional Fund Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.